Roles, Resources, and Relationships: The Stakeholder Framework Behind Successful Myeloma Care Transitions

This episode, titled 'Roles, Resources, and Relationships: The Stakeholder Framework Behind Successful Myeloma Care Transitions,' features oncology pharmacists discussing the following critical questions:

Who were the key stakeholders involved in both the academic and community sides and what did each of them contribute to making the transition successful?

What resources, tools, or protocols were shared between centers, and how were those handoffs structured?

Led by the moderator, the panelists examined the specific contributions each stakeholder makes to a successful bispecific antibody care transition, emphasizing that effective handoffs require engagement across the full care team and that each member plays a distinct and irreplaceable role in ensuring that the receiving site is fully prepared before a patient arrives. The discussion also highlighted the critical importance of REMS enrollment and side effect education as foundational elements of community site onboarding, with the panelists noting that community centers newer to bispecific antibody administration may not have prior experience with cytokine release syndrome (CRS) or neurotoxicity, making the proactive sharing of institutional CRS prevention and management protocols between academic and community partners an essential act of clinical generosity that ultimately benefits patients regardless of where they receive care. The panelists further outlined the practical patient-facing tools that have proven particularly valuable in supporting safe transitions, including manufacturer-provided supportive care kits equipped with blood pressure cuffs, pulse oximeters, and thermometers for remote monitoring, as well as wallet cards and bracelets that identify patients as bispecific antibody recipients, ensuring that emergency department staff anywhere in the country have the information and contacts needed to provide appropriate care if a patient presents with a complication far from their treating institution.

Throughout the conversation, the experts provide a comprehensive reflection on the field and the factors that may shape how clinicians approach care moving forward.

In the next episode, 'When Transitions Break Down: Real-World Challenges and Lessons Learned in Myeloma Care Handoffs,' panelists will continue their discussion on multiple myeloma and highlight real-world cases where academic-to-community transitions did not go as planned, examining the specific breakdowns in communication, REMS readiness, and logistical coordination that created challenges for patients and providers, and the lessons each institution took away from those experiences.